By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Seattle Genetics, Inc. 

21823 - 30th Drive S.E.

Bothell  Washington  98021  U.S.A.
Phone: 425-527-4000 Fax: 425-527-4001


SEARCH JOBS
Committed to improving patient outcomes
At Seattle Genetics, we are committed to developing innovative antibody-based therapies that improve clinical outcomes for patients with cancer and autoimmune diseases. We are dedicated to addressing unmet medical need, and strive to achieve that goal through an unwavering commitment to excellence in clinical development.

Focusing on Clinical Development
Seattle Genetics is a clinical stage biotechnology company advancing a broad product pipeline of antibody-based therapies. Our lead program, brentuximab vedotin (SGN-35), is in a pivotal trial under a Special Protocol Assessment with the FDA for patients with relapsed or refractory Hodgkin lymphoma. Brentuximab vedotin is empowered by Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology. In addition, we are conducting clinical trials with four other product candidates, lintuzumab (SGN-33), dacetuzumab (SGN-40) and SGN-75, for the treatment of cancer, and SGN-70, for autoimmune diseases. We are also advancing a pipeline of promising preclinical candidates and have robust research and development capabilities that are our engine for innovation and long-term growth.

Our proprietary ADC technology empowers antibodies by stably linking them to cell-killing drug payloads. The drug payload is inactive until released from the antibody inside the targeted cancer cell, thereby sparing normal tissue the toxicity of traditional chemotherapy. In addition to brentuximab vedotin, SGN-75 is an ADC that is in a phase I clinical trial and we are developing several preclinical ADC product candidates, including ASG-5ME, which is advancing towards a planned 2010 clinical trial for solid tumors.

Expanding Our Opportunities Through Collaboration
Collaborating with leading biopharmaceutical companies is a cornerstone of Seattle Genetics' business strategy. Product-focused collaborations, such as our exclusive worldwide collaboration agreement with Genentech (a wholly owned member of the Roche Group) to develop and commercialize dacetuzumab, provide significant near- and mid-term funding while bringing in additional resources and expertise to support, advance and expand promising development programs. Collaboration and license agreements around our proprietary ADC technology also generate cash for the company - more than $75 million to date - while providing further clinical validation of the ADC platform and, in some cases, opening the door to new product development opportunities.


Key Statistics


Email: contact@seagen.com
Ownership: Public

Web Site: Seattle Genetics, Inc.
Employees:
Symbol: SGEN
 



Industry
Biotechnology


Collaborations

Celera Corporation  Seeking to jointly discover and develop antibody-based therapies for cancer.

Applied Molecular Evolution/Eli Lilly 

MedImmune 





Company News
Seattle Genetics, Inc. (SGEN) To Host Conference Call And Webcast Discussion Of Third Quarter 2014 Financial Results On October 30, 2014 10/14/2014 11:45:34 AM
Seattle Genetics, Inc. (SGEN) To Host Conference Call And Webcast On September 29, 2014 Regarding Top-Line Data From ADCETRIS┬« (brentuximab vedotin) Phase 3 AETHERA Clinical Trial 9/29/2014 11:41:50 AM
Seattle Genetics, Inc. (SGEN) And Takeda Pharmaceutical Co. Ltd. (TKPYY) Announce Positive Data From Phase 3 AETHERA Clinical Trial Of ADCETRIS┬« (Brentuximab Vedotin) For Consolidation In Post-Transplant Hodgkin Lymphoma 9/29/2014 11:39:13 AM
Seattle Genetics, Inc. (SGEN), Takeda Pharmaceutical Co. Ltd. (TKPYY)'s Cancer Drug Meets Main Goal In Phase 3 Trial 9/29/2014 6:36:12 AM
Seattle Genetics, Inc. (SGEN) Highlights Updated Progression-Free Survival And Overall Survival Data From ADCETRIS® (Brentuximab Vedotin) Frontline PTCL Phase 1 Clinical Trial At The ESMO 2014 Congress 9/25/2014 11:53:56 AM
Seattle Genetics, Inc. (SGEN), Genmab A/S (GEN.CO) Partner In $211 Million Antibody-Drug Pact 9/10/2014 6:39:01 AM
Seattle Genetics, Inc. (SGEN) To Present At Morgan Stanley (MST) Healthcare Conference 9/2/2014 11:00:10 AM
Seattle Genetics, Inc. (SGEN) Initiates Phase 1 Clinical Trial Of Antibody-Drug Conjugate SGN-CD70A For Non-Hodgkin Lymphoma And Renal Cell Carcinoma 8/12/2014 8:21:24 AM
Seattle Genetics, Inc. (SGEN) Reports Second Quarter 2014 Financial Results 8/1/2014 9:02:18 AM
Seattle Genetics, Inc. (SGEN) To Host Conference Call And Webcast Discussion Of Second Quarter 2014 Financial Results On July 31, 2014 7/9/2014 11:00:27 AM
12345678910...
//-->